A review of microscopic colitis, a chronic, intermittent inflammatory bowel disease that predominantly affects older women and typically presents with frequent watery, non-bloody stools.

Today, AbbVie (NYSE: ABBV) has announced two positive updates for Canadians living with UC, including those in Ontario and ...

Treatment failure occurs when an ulcerative colitis medication isn’t helping symptoms. Most important, know that it’s not your fault. Learn what to do next.

MRM Health, a clinical-stage biopharmaceutical company developing therapeutics for immune-mediated diseases, which unlock the power of the microbiome to restore immune balance, today announced that ...

Ulcerative colitis treatment drug Omvoh, from Eli Lilly, was linked to sustained clinical remission after 4 years, according to new trial data. Image credit: Plexi Images/GHI/UCG/Universal Images ...

Our gut is the key to much of our body's overall health, which is why diseases like ulcerative colitis can be so detrimental. Ulcerative colitis is one of the most common inflammatory bowel diseases.

How Does Tremfya Work for Ulcerative Colitis? Tremfya is a monoclonal antibody that reduces inflammation. The main ingredient in Tremfya is a medicine called guselkumab. This medicine blocks a ...

Microscopic colitis is a lifelong condition that causes symptoms such as diarrhea and abdominal pain. It is a type of inflammatory bowel disease (IBD). While there is no cure for microscopic colitis, ...

Ulcerative Colitis Market grows at 5.4% CAGR (2025–2033), reaching US$ 12.79 Billion on rising biologic adoption, biosimilars, and personalized IBD therapies. North America leads the ulcerative ...

Crohn’s disease and ulcerative colitis, the two main types of inflammatory bowel disease (IBD), affect millions and can bring ...

The MarketWatch News Department was not involved in the creation of this content. Ulcerative Colitis Market Poised for Strong Expansion During the Forecast Period (2025-2034) Driven by Biologic and ...